Among adults with acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) with planned ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...

A year prior, the Biden administration gave different reasons for the start of the overdose deaths decline, describing its work to distribute more of the opioid-overdose reversing drug naloxone, ...

Learn how the Kenney Rule helps insurers manage risk by maintaining a balanced ratio of unearned premiums to policyholders' surplus, ensuring financial stability.

Cardiac rehab (CR) remains one of the most underutilized interventions in cardiovascular medicine despite overwhelming evidence that it saves lives, improves quality of life and is cost effective.

In an environment where the cost of inaction eclipses the cost of innovation, evaluating the ROI of risk reduction technology is a critical skill for enterprise leaders. Although enterprise risk is ...

A cardiologist recently suggested that I should consider taking a statin because of my “borderline” cholesterol level. So, I took a dive into the details of statin therapy. I learned that although ...

NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac events (MACE) in patients with atherosclerosis or high-risk diabetes, but ...

NEW ORLEANS — The first global randomized trial of the PCSK9 inhibitor evolocumab for the prevention of a primary major adverse cardiovascular event (MACE) found a relative reduction in risk similar ...

(RTTNews) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular events (MACE) ...

THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved ...